Literature DB >> 28535416

The role of timing in the treatment of spinal cord injury.

Amene Saghazadeh1, Nima Rezaei2.   

Abstract

Regeneration failure after primary spinal cord injury (SCI) leads to diverse clinical complications in a severity- and level of SCI-dependent manner. The cost of treating both of them (initial regeneration failure and following complications) would be prohibitive, particularly in less developed nations. The well-recognized circumstances arose from primary SCI include excitotoxicity and inflammation. SCI increases concentrations of extracellular amino acids (EAAs) in the severity-dependent manner and the maximum level of EAAs at the injury site will be reduced by distance from the injury site. Increased concentrations of EAAs and their signaling result in energy and metabolic changes and eventually neurotoxicity. Therefore EAAs play a crucial role in moving towards secondary stage of SCI. There is a close correspondence between severity of SCI and intensity of acute inflammatory response, which includes proinflammatory cytokines (IL-1β, TNF-α, and IL-6) and immune cells (neutrophils, microglia, and mast cells). The communication between microglia and astrocytes mediate formation of astroglial scar. The scar is thought to diminish the spread of inflammation and lesion volume, and on the other side poses an obstacle to achieving axon regeneration. Moreover, mast cells exert an anti-inflammatory role in the ground of injured spinal cord by degradation of proinflammatory mediators, while mast cells-derived histamine may cause excitotoxicity. Therefore research suggests a very double-sword remark about the work of inflammatory mediators in the injured spinal cord. Myelin associated inhibitors (MAIs) are among the growing list of extrinsic inhibitors of neuroregeneration in the injured-CNS. They function via NgR-dependent mechanisms. The time for intervention by NgR antagonists must be fixed according to the expression pattern of this receptor and its dependent MAIs after SCI. Altogether, experimental studies suggest potential benefits of combating EAAs, inflammatory mediators, and MAIs during the first minutes, hours and weeks after SCI, respectively. However, acute inflammation initially induced by SCI tends to be permanent, even at several years after SCI. This supports the notion that paying attention to inflammation must persist through time. The consideration of seconds-dependent state of spinal cord after primary injury is a very therapeutic and also preventive approach against future possible complications. It is thereby possible to propose "timing", which is perfectly practicable throughout the world, as an effective campaign against the final failure of SCI.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Complications; Cytokines; Excitotoxicity; Inflammation; Neurodegeneration; Regeneration; Spinal cord injury; Timing

Mesh:

Substances:

Year:  2017        PMID: 28535416     DOI: 10.1016/j.biopha.2017.05.048

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  12 in total

1.  Expression and Cellular Localization of IFITM1 in Normal and Injured Rat Spinal Cords.

Authors:  Ying Wang; Yu-Hong Lin; Yan Wu; Zong-Feng Yao; Jie Tang; Lin Shen; Rui Wang; Shu-Qin Ding; Jian-Guo Hu; He-Zuo Lü
Journal:  J Histochem Cytochem       Date:  2018-01-04       Impact factor: 2.479

Review 2.  Pros and Cons: Autophagy in Acute Spinal Cord Injury.

Authors:  Zheng Li; Tianshi Chen; Yuanwu Cao; Xiaoxing Jiang; Haodong Lin; Jian Zhang; Zixian Chen
Journal:  Neurosci Bull       Date:  2019-04-04       Impact factor: 5.203

Review 3.  Mechanism of Neuroprotection Against Experimental Spinal Cord Injury by Riluzole or Methylprednisolone.

Authors:  Cynthia Sámano; Andrea Nistri
Journal:  Neurochem Res       Date:  2017-12-30       Impact factor: 3.996

Review 4.  Regenerative Therapies for Spinal Cord Injury.

Authors:  Nureddin Ashammakhi; Han-Jun Kim; Arshia Ehsanipour; Rebecca D Bierman; Outi Kaarela; Chengbin Xue; Ali Khademhosseini; Stephanie K Seidlits
Journal:  Tissue Eng Part B Rev       Date:  2019-10-23       Impact factor: 6.389

Review 5.  Neurochemical biomarkers in spinal cord injury.

Authors:  Brian K Kwon; Ona Bloom; Ina-Beate Wanner; Armin Curt; Jan M Schwab; James Fawcett; Kevin K Wang
Journal:  Spinal Cord       Date:  2019-07-04       Impact factor: 2.772

6.  Inhibition of MSK1 Promotes Inflammation and Apoptosis and Inhibits Functional Recovery After Spinal Cord Injury.

Authors:  Ze-Xiang Zhong; Si-Si Feng; Shao-Ze Chen; Zhen-Ming Chen; Xuan-Wei Chen
Journal:  J Mol Neurosci       Date:  2019-03-27       Impact factor: 3.444

7.  Injectable, macroporous scaffolds for delivery of therapeutic genes to the injured spinal cord.

Authors:  Arshia Ehsanipour; Mayilone Sathialingam; Laila M Rad; Joseph de Rutte; Rebecca D Bierman; Jesse Liang; Weikun Xiao; Dino Di Carlo; Stephanie K Seidlits
Journal:  APL Bioeng       Date:  2021-03-09

8.  Long non-coding RNA-small nucleolar RNA host gene 7 regulates inflammatory responses following spinal cord injury by regulating the microRNA-449a/TNF-α-induced protein 3-interacting protein 2 axis.

Authors:  Chunlei He; Jianhua Xiao; Yongjun Ye; Shiqiao Huang; Yanchun Zhong; Lulin Liu; Wuyang Liu; Sheng Liu
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

Review 9.  Potential immunotherapies for traumatic brain and spinal cord injury.

Authors:  Raj Putatunda; John R Bethea; Wen-Hui Hu
Journal:  Chin J Traumatol       Date:  2018-04-18

10.  NeuroRegen Scaffolds Combined with Autologous Bone Marrow Mononuclear Cells for the Repair of Acute Complete Spinal Cord Injury: A 3-Year Clinical Study.

Authors:  Wugui Chen; Ying Zhang; Sizhen Yang; Jing Sun; Hao Qiu; Xu Hu; Xiaojian Niu; Zhifeng Xiao; Yannan Zhao; Yue Zhou; Jianwu Dai; Tongwei Chu
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.